<?xml version="1.0" encoding="UTF-8"?>
<p id="par0010">The novel Coronavirus (2019-nCoV) was isolated from a cluster of patients who developed respiratory tract symptoms (fever, cough, shortness of breath) in Wuhan Province in late December and named as a new coronavirus COVID-19 [
 <xref rid="bib0010" ref-type="bibr">2</xref>]. On 30 January 2020, World Health Organization (WHO) has declared “Public Health Emergency of International Concern” as the 2019-nCoV outbreak continued to be spreaded outside of China and a pandemic on 11 March 2020 to be posed a threat to public health worldwide [
 <xref rid="bib0015" ref-type="bibr">3</xref>,
 <xref rid="bib0020" ref-type="bibr">4</xref>]. Although the fatality rate of 2019-nCoV was not as high as MERS-CoV it has kept on rather a high rate as the emergence of the outbreak. On the other hand it was likely to be related to all aspects of the pathogenesis of COVID-19 infection that has not been clarified as well as the fact that antiviral treatment for the agent has not been developed yet. Current treatment approaches include supportive therapy, such as prevention and treating seconder infections and complications. In this context, passive immunization has been became the main topic for the treatment based on historical experiences. “Passive Immune Transfer” is defined as the use of immune plasma for critically ill hospitalized patients for therapeutic purposes. Immune plasma had been used previously for the treatment of 2009–2012 H1N1 influenza virus, 2003 SARS-CoV-1 and 2012 MERS-CoV epidemics successfully [
 <xref rid="bib0025" ref-type="bibr">5</xref>,
 <xref rid="bib0030" ref-type="bibr">6</xref>]. Passive immune antibodies may neutralize viruses or reduce target organ damages. In this scope convalescent plasma or immunoglobulin has been decided to be collected from the patients who had been recovered from COVID-19 to prevent or to treat COVID-19 infection.
</p>
